Fundamental Analysis

ABBOTT INDIA LIMITED 

{Ticker : 500488  { BUY: Rs. 14400.00  {Target: Rs. 16000

Abbott India Limited is a healthcare company engaged in the pharmaceutical business. The company has a portfolio of science-based offerings in diagnostics, medical devices, nutritional and branded generic pharmaceuticals. Its medical and pharmaceutical products include insulin injections, antidysentery drugs, vitamin preparations, penicillin preparations and a variety of household remedies. On the standalone quarterly front, net sales for the quarter ended December 2019 was Rs 1,078.25 crore, up by 13.78 per cent from Rs 947.65 crore in Q3FY19. The company reported an operating profit of Rs 250.55 crore in Q3FY20, increasing by 39.40 per cent from Rs 179.73 crore in Q3FY19. Net profit was reported at Rs 186.69 crore in Q3FY20, increasing by 59.50 per cent from Rs 117.05 crore in the corresponding period for the previous fiscal year. Abbott’s strong growth track in power brands and capability of new launches on a consistent basis seems positive for the immediate outlook of the stock. We thus, recommend a BUY.